Biomarin Pharmaceutical (BMRN) Retained Earnings (2009 - 2026)
Biomarin Pharmaceutical (BMRN) posted Retained Earnings of $259.7 million for Q1 2026, up 2027.8% on a QoQ basis from -$13.5 million in Q4 2025, and up 1256.24% year-over-year from $19.2 million in Q1 2025.
Biomarin Pharmaceutical (BMRN) Retained Earnings (2009 - 2026) Analysis & Trends
Biomarin Pharmaceutical's Retained Earnings history runs 18 years deep, the most recent figure standing at $259.7 million for Q1 2026.
- Quarterly Retained Earnings rose 1256.24% year-over-year to $259.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $259.7 million (up 1256.24% YoY) and the FY2025 annual result came in at -$13.5 million, up 93.08% from the prior year.
- Retained Earnings was $259.7 million for Q1 2026 at Biomarin Pharmaceutical, up from -$13.5 million in the prior quarter.
- Across five years, Retained Earnings topped out at $259.7 million in Q1 2026 and bottomed at -$804.9 million in Q1 2022.
- A 5-year average of -$152.2 million and a median of -$1.0 million in 2024 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2022 — Retained Earnings tumbled 16184.95% — and 2025, when it soared 4217.83%.
- Biomarin Pharmaceutical's Retained Earnings stood at -$789.2 million in 2022, then surged by 96.35% to -$28.8 million in 2023, then slumped by 576.31% to -$194.7 million in 2024, then soared by 93.08% to -$13.5 million in 2025, then jumped by 2027.8% to $259.7 million in 2026.
- Business Quant data shows BMRN's Retained Earnings at $259.7 million in Q1 2026, -$13.5 million in Q4 2025, and $200.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -527.87 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -27.89 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 12.91 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 115.82 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 11.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -622,000.00 |
| 10 | Biomarin Pharmaceutical | 11.33 Bn | 9.11 Bn | 571.21 Mn | 259.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 259.73 Mn |
| Dec 31, 2025 | -13.47 Mn |
| Sep 30, 2025 | 200.78 Mn |
| Jun 30, 2025 | 231.52 Mn |
| Mar 31, 2025 | 19.15 Mn |
| Dec 31, 2024 | -194.70 Mn |
| Sep 30, 2024 | 4.65 Mn |
| Jun 30, 2024 | 26.80 Mn |
| Mar 31, 2024 | -1.05 Mn |
| Dec 31, 2023 | -28.79 Mn |
| Sep 30, 2023 | 6.26 Mn |
| Jun 30, 2023 | -18.62 Mn |
| Mar 31, 2023 | -738.35 Mn |
| Dec 31, 2022 | -789.20 Mn |
| Sep 30, 2022 | 30.75 Mn |
| Jun 30, 2022 | -777.23 Mn |
| Mar 31, 2022 | -804.89 Mn |
| Dec 31, 2021 | 14.43 Mn |
| Sep 30, 2021 | 10.24 Mn |
| Jun 30, 2021 | -831.30 Mn |